肿瘤患者是全关节置换捆绑支付系统中的高成本离群者
本研究回顾性分析了2016年4月1日至2018年6月31日单中心加入CJR捆绑支付系统的314例患者(12例原发或转移性肿瘤,302例骨关节炎),发现肿瘤患者总住院费用、住院时长和转至专业护理机构的比例均显著高于骨关节炎患者,且调整骨折状态后肿瘤患者超出CJR目标价格的风险比为5.36。作者建议将肿瘤患者排除在CJR捆绑支付之外。
要点
- 肿瘤患者总住院费用均值40862美元,骨关节炎组16356美元(P < .001)。
- 肿瘤患者住院时长6.75天,骨关节炎组2.0天(P < .001)。
核心结论
- 加入CJR捆绑支付模式的肿瘤患者费用显著更高且费用变异性更大,作者建议将肿瘤患者排除在CJR捆绑支付之外。
研究设计与样本
- 回顾性综述,纳入2016年4月1日至2018年6月31日单中心加入CJR捆绑支付系统的所有患者,共314例(12例原发或转移性肿瘤,302例骨关节炎)。
主要发现
- 肿瘤患者中58%超出目标价格,骨关节炎患者中16%超出目标价格。
- 肿瘤患者总住院费用均值40862美元,骨关节炎组16356美元(P < .001)。
- 肿瘤组住院时长6.75天,骨关节炎组2.0天(P < .001)。
- 肿瘤患者转至专业护理机构的比例67%,骨关节炎组27%(P = .006);专业护理机构 episode 费用肿瘤组18852美元,骨关节炎组7731美元(P = .04)。
临床怎么用
- 作者建议将肿瘤患者排除在CJR捆绑支付之外。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2016, the Centers for Medicare and Medicaid Services began its first mandatory bundled payment program, the Comprehensive Care for Joint Replacement (CJR) model, which covers a 90-day episode of care. This study determined whether oncology patients enrolled in the CJR bundle incur higher hospital costs than patients with osteoarthritis (OA). METHODS: A retrospective review of all patients enrolled in the CJR bundled payments system from April 1, 2016 to June 31, 2018 at a single academic medical center was conducted. To determine whether tumor patients had higher total episode costs, this group was compared to patients diagnosed with OA using a 2-tailed t-test. To adjust for moderators of total hospital costs, we used generalized linear regression with a log-link, including multiple variables abstracted from chart review. RESULTS: Three hundred fourteen patients met inclusion criteria (12 primary or metastatic tumors, 302 OA). Fifty-eight percent of tumor patients were over the target price vs 16% of OA patients. The mean tumor patient had $40,862 for total internal hospital costs compared to $16,356 in the OA group (P < .001). Length of stay was greater in the tumor group (6.75 vs 2.0 days, P < .001). A greater percentage of tumor patients were discharged to a skilled nursing facility (67% vs 27%, P = .006) with significantly higher skilled nursing facility episode costs ($18,852 vs $7731, P = .04). With adjustment for fracture status, tumor patients were 5.36 times more likely to exceed the CJR target price than OA patients (risk ratio 5.36, confidence interval 3.44-8.35, P < .001) and 50 times more likely to be outliers over the regional threshold than OA patients (risk ratio 50.33, confidence interval 16.33-155.19, P < .001). CONCLUSION: Oncology patients enrolled in the CJR bundled payment model incur significantly higher costs and have higher cost variability than patients with OA. We recommend that oncology patients be excluded from the CJR bundle.
引用
- Woelber E, Gundle KR, Geddes J, et al. Oncology Patients Are High Cost Outliers in Total Joint Replacement Bundled Payment Systems. J Arthroplasty. 2019. PMID: 31521444. doi:10.1016/j.arth.2019.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。